Quoin Pharmaceuticals, Ltd.
QRX003
Netherton Syndrome
Date
TBD
FDA decision · Date TBD estimated
What's at stake
The FDA's approval decision on QRX003 for Netherton Syndrome is due Date TBD. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 14h ago
“A request for proprietary name review and final approval for QYLEKI will be included in a New Drug Application (NDA) for QRX003.”